ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II–IV Melanoma Patients and Their Clinicians
Crossref DOI link: https://doi.org/10.1245/s10434-019-08020-4
Published Online: 2019-10-31
Published Print: 2020-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Livingstone, Ann
Morton, Rachael L.
Text and Data Mining valid from 2019-10-31
Version of Record valid from 2019-10-31
Article History
Received: 16 October 2019
First Online: 31 October 2019
Disclosures
: The authors report no conflicts of interest.